CTLA4 gene variations and haplotypes in patients with lung cancer

被引:34
|
作者
Khaghanzadeh, Narges [1 ]
Erfani, Nasrollah [2 ]
Ghayumi, Mohammad Ali [3 ]
Ghaderi, Abbas [1 ,2 ]
机构
[1] Shiraz Univ Med Sci, Dept Immunol, Shiraz, Iran
[2] Shiraz Univ Med Sci, Inst Canc Res, Shiraz, Iran
[3] Shiraz Univ Med Sci, Dept Internal Med, Shiraz, Iran
关键词
SYSTEMIC-LUPUS-ERYTHEMATOSUS; BREAST-CANCER; JAPANESE PATIENTS; PROMOTER REGION; POLYMORPHISM; ASSOCIATION; ANTIGEN-4; SUSCEPTIBILITY; POPULATION; ALLELE;
D O I
10.1016/j.cancergencyto.2009.09.001
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The CTLA4 protein downmodulates and terminates immune responses by sending inhibitory signals to activated T cells. In this study, six main single-nucleotide polymorphisms of the CTLA4 gene were investigated in 127 lung cancer patients and 124 healthy control subjects: -1722 T/C, -1661 A/G, -318 CIT. +49A1G, +1822 C/T, and +6230 A/G (CT60). Statistical analyses revealed no significant differences in the frequencies of genotypes, alleles, and haplotypes between patients and control subjects. We also could not find significant association between CTLA4 variants and any defined lung tumor type. These six single-nucleotide polymorphisms in CTLA4 were not associated with susceptibility to lung cancer in Iranian population. (C) 2010 Elsevier Inc. All rights reserved.
引用
收藏
页码:171 / 174
页数:4
相关论文
共 50 条
  • [31] Haplotype tagging efficiency in worldwide populations in CTLA4 gene
    Ramírez-Soriano, A
    Lao, O
    Soldevila, M
    Calafell, F
    Bertranpetit, J
    Comas, D
    GENES AND IMMUNITY, 2005, 6 (08) : 646 - 657
  • [32] Pharmacogenetic analysis of CTLA4 gene polymorphisms and response to tremelimumab in patients with advanced melanoma
    Richmond, J.
    Gao, F.
    Wood, L.
    Bulanhagui, C. A.
    Penny, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [33] MHC class II region, CTLA4 gene, and ophthalmopathy in patients with Graves' disease
    Allahabadia, A
    Heward, JM
    Nithiyananthan, R
    Gibson, SM
    Reuser, TTQ
    Dodson, PM
    Franklyn, JA
    Gough, SCL
    LANCET, 2001, 358 (9286): : 984 - 985
  • [34] CTLA4 gene and Graves' disease: association of Graves' disease with the CTLA4 exon 1 and intron 1 polymorphisms, but not with the promoter polymorphism
    Vaidya, B
    Oakes, EJC
    Imrie, H
    Dickinson, AJ
    Perros, P
    Kendall-Taylor, P
    Pearce, SHS
    CLINICAL ENDOCRINOLOGY, 2003, 58 (06) : 732 - 735
  • [35] Evidence for CTLA4 as a susceptibility gene for systemic lupus erythematosus
    Marta Barreto
    Eugénia Santos
    Ricardo Ferreira
    Constantin Fesel
    Maria Francisca Fontes
    Clara Pereira
    Berta Martins
    Rita Andreia
    João Faro Viana
    Francisco Crespo
    Carlos Vasconcelos
    Carlos Ferreira
    Astrid Moura Vicente
    European Journal of Human Genetics, 2004, 12 : 620 - 626
  • [36] CTLA4 gene polymorphisms and multiple sclerosis in Northern Ireland
    Heggarty, Shirley
    Suppiah, Vijayaprakash
    Silversides, Jonathan
    O'Doherty, Catherine
    Droogan, Aidan
    McDonnell, Gavin
    Hawkins, Stanley
    Graham, Colin
    Vandenbroeck, Koen
    JOURNAL OF NEUROIMMUNOLOGY, 2007, 187 (1-2) : 187 - 191
  • [37] No association of CTLA4 gene with celiac disease in the Basque population
    Martín-Pagola, A
    de Nanclares, GP
    Vitoria, JC
    Bilbao, JR
    Ortiz, L
    Zubillaga, P
    Castaño, L
    JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2003, 37 (02): : 142 - 145
  • [38] No evidence for an association of the CTLA4 gene with bipolar I disorder
    Jun, TY
    Lee, KU
    Pae, CU
    Kweon, YS
    Chae, JH
    Bahk, WM
    Kim, KS
    Lew, TY
    Han, H
    PSYCHIATRY AND CLINICAL NEUROSCIENCES, 2004, 58 (01) : 21 - 24
  • [39] CTLA4 polymorphisms in Spanish patients with rheumatoid arthritis
    Gonzalez-Escribano, MF
    Rodriguez, R
    Valenzuela, A
    Garcia, A
    Garcia-Lozano, JR
    Nuñez-Roldan, A
    TISSUE ANTIGENS, 1999, 53 (03): : 296 - 300
  • [40] CTLA4 polymorphisms in patients with multiple sclerosis.
    Waliszewska, A
    Buckle, GJ
    Hafler, DA
    CLINICAL IMMUNOLOGY, 2002, 103 (03) : S131 - S131